Precision medicine in oncology /

Saved in:

Bibliographic Details
Corporate Author:	ProQuest (Firm)
Other Authors:	Radosevich, James A. (James Andrew) (Editor), Aydogan, Bulent (Editor)
Format:	Electronic eBook
Language:	English
Published:	Hoboken, NJ : Wiley-Blackwell, 2021.
Subjects:	Cancer > Radiotherapy. Neoplasms > radiotherapy. Precision Medicine > methods.
Online Access:	Connect to this title online (unlimited simultaneous users allowed; 325 uses per year)

Table of Contents:

Machine generated contents note: 1.1. Introduction / Anne Blaes / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.1.1. Definition of Precision Medicine in Oncology / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Ardaman Shergill / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Maya Viner
1.1.2. DNA and RNA Sequencing Techniques / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2. Precision Medicine in Specific Tumors / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1. Lung Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.1. Adenocarcinoma / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.2. Squamous Cell Carcinoma / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.3. Small-Cell Lung Carcinoma (SCLC) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.4. Epidermal Growth Factor Receptor (EGFR) Mutations / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.5. Anaplastic Lymphoma Kinase (ALK) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.6. BRAF, ROS1, MET / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.7. KRAS / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.1.8. Other: RET, NTRK / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.2. Head and Neck Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.2.1. HPV-Positive Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.2.2. HPV-Negative Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.2.3. Targeting the Epidermal Growth Factor Receptor (EGFR) Pathway / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.2.4. Thyroid Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Maya Viner / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill
1.2.2.5. Other Targets / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.3. Hematological Malignancies / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.3.1. Lymphoma / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.3.2. Leukemia / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.3.3. Myelodysplastic Syndrome / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.4. Gynecologic Malignancies / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.4.1. Cervical / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.4.2. Uterine / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.4.3. Ovarian / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.5. Melanoma / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.6. Gastrointestinal Malignancies / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.6.1. Gastroesophageal Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.6.2. Colorectal Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7. Breast Cancer / Arkadiusz Z. Dudek / Amit Kulkarni / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.1. Basal-Like, or Triple Negative Breast Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.2. Luminal A/B, or Hormone Positive / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.3. HER2 Positive Breast Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.4. Immunotherapy / Anne Blaes / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.5. Germline Testing in Breast Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.7.6. Conclusion / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.8. Genitourinary Malignancies / Arkadiusz Z. Dudek / Amit Kulkarni / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.8.1. Prostate Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.8.2. Renal Cell Cancer (RCC) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.8.3. Urothelial Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9. Pediatric Cancers / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9.1. Introduction / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9.2. Leukemia and Lymphoma / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9.3. Central and Peripheral Nervous System Tumors / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
Contents note continued: 1.2.9.4. Bone and Soft Tissue Sarcomas / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9.5. Other Embryonal Tumors / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.9.6. Conclusion / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.10. Cancers of Unknown Primary Origin / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.10.1. Diagnosis / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.10.2. Gene Expression Profiling / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.10.3. Mutational Testing with Next-Generation Sequencing (NGS) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.2.10.4. Treatment / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3. Biomarkers for Immunotherapy of Cancer / Anne Blaes / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.1. PD-L1 / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.2. Soluble PD-L1 (sPD-L1) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.3. Combined Positive Score (CPS) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.4. Tumor Microenvironment / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.5. Tumor Mutational Burden (TMB) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.6. Microsatellite Instability (MSI) / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.7. MMR Deficiency / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.8. Peripheral Blood Absolute Neutrophil Count/Absolute Lymphocyte Count / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.3.9. Microbiome / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.4. Clinical Trial Design in the Era of Precision Oncology / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.5. Ethical, Legal, and Social Issues of Precision Oncology / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Maya Viner / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill
1.5.1. Ethical Issues / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.5.2. Legal Issues / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.5.3. Social Issues / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
1.6. Databases, Data Sharing, and Challenges of Precision Oncology / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
References / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
2. Blood-Based Biomarkers for the Diagnosis and Prognosis of Cancer / Arkadiusz Z. Dudek / Kate Baxstrom / Sushma Bharadwaj / Anne Blaes / Amit Kulkarni / Emil Lou / Vijeyaluxmy Nehru / Emma Rabinovich / Ardaman Shergill / Maya Viner
2.1. Introduction / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.2. Importance of Blood-Based Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.3. Circulating Proteins as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.4. Circulating Long Non-coding RNAs as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.5. Circulating miRNAs as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.6. Circulating Autoantibodies as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.7. Circulating Tumor DNA as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.8. Metabolites as Biomarkers / Chandi C. Mandal / Shreetama Bandyopadhayaya
2.9. Lipids as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.10. Exosomes as Biomarkers / Shreetama Bandyopadhayaya / Chandi C. Mandal
2.11. Conclusion / Shreetama Bandyopadhayaya / Chandi C. Mandal
References / Shreetama Bandyopadhayaya / Chandi C. Mandal
3. Application of Circulating Cell-free DNA for Personalized Cancer Therapy / Shreetama Bandyopadhayaya / Chandi C. Mandal
3.1. Introduction / Indranil Chattopadhyay
3.2. Drawbacks and Challenges of Invasive Tumor Tissue in Treatment and Diagnosis of Cancer / Indranil Chattopadhyay
3.3. Importance of Noninvasive Biomarkers in Treatment and Diagnosis of Cancer / Indranil Chattopadhyay
3.4. Liquid Biopsy: cfDNA and ctDNA / Indranil Chattopadhyay
3.4.1. Biogenesis of ctDNA: Mechanisms of Release, Characteristics, Quantity, and Quality / Indranil Chattopadhyay
3.4.2. Role of Preanalytical Factors that Affect cfDNA Measurements / Indranil Chattopadhyay
3.5. Practical Approach to Estimate ctDNA in Liquid Biopsy / Indranil Chattopadhyay
3.5.1. Isolation of cfDNA and ctDNA / Indranil Chattopadhyay
3.5.2. Analysis of ctDNA by Real-Time Quantitative PCR / Indranil Chattopadhyay
3.5.3. Analysis of ctDNA by Digital PCR (dPCR) / Indranil Chattopadhyay
3.5.4. Analysis of ctDNA by Beads, Emulsion, Amplification, and Magnetics (BEAMing) / Indranil Chattopadhyay
3.5.5. Analysis of ctDNA by Next-Generation Sequencing (NGS) / Indranil Chattopadhyay
3.6. Clinical Application of ctDNA Detection in Various Cancers / Indranil Chattopadhyay
3.6.1. Clinical Applications of ctDNA in Lung Cancer / Indranil Chattopadhyay
3.6.2. Clinical Application of ctDNA in Head and Neck Cancer / Indranil Chattopadhyay
3.6.3. Clinical Utility of Circulating Tumor DNA in Pancreatic Cancer / Indranil Chattopadhyay
3.6.4. Clinical Utility of Circulating Tumor DNA in Early and Metastatic Breast Cancer / Indranil Chattopadhyay
3.6.5. Clinical Utility of Circulating Tumor DNA in Colorectal Cancer / Indranil Chattopadhyay
3.6.6. Clinical Utility of Circulating Tumor DNA in Melanoma / Indranil Chattopadhyay
3.7. Clinical Utility of Methylation in ctDNA in Personalized Oncology / Indranil Chattopadhyay
3.8. Conclusion / Indranil Chattopadhyay
References / Indranil Chattopadhyay
4. Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl-2 in Head and Neck Squamous Cell Carcinoma (HNSCC) / Indranil Chattopadhyay
4.1. Introduction / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2. Epidermal Growth Factor Receptor (EGFR) / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.1. EGFR Structure and Ligands / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.2. Physiology / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.3. EGFR Expression and Genetic Changes / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
Contents note continued: 4.2.3.1. EGFR Expression in HNSCC / Sarah Khan / Paramjeet Khosla / Lawrence Feldman / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint
4.2.3.2. Normal Adjacent Oral Mucosa and Pre-malignant Lesions / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.4. EGFR Genetic Changes: Gene Copy Numbers, Amplifications, and Mutations in HNSCC / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.4.1. Association of EGFR Expression or Genetic Changes with HPV Infection / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.5. EGFR as a Prognostic and Predictive Marker / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.5.1. EGFR as a Prognostic Marker / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.5.2. EGFR as a Predictive Marker / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.6. Future Perspectives / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.6.1. EGFR in Immuno-SPECT or PET Imaging / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.2.6.2. Molecular Profiling for Precision Medicine / Paramjeet Khosla / Lawrence Feldman / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan
4.3. TP53 Mutations in Head and Neck Cancer / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.1. Pathogenesis and Prevalence / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.2. Risk Factors / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.3. TP53 Structure and Physiology / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.3.1. TP53 Structure / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.3.2. TP53 as a Tumor Suppressor Gene / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.4. TP53 Gain of Function Properties / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.5. TP53 as a Prognostic and Predictive Marker / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.3.6. Therapeutic Strategies Targeting TP53 / Lawrence Feldman / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla
4.4. P16 and Cyclin Dl Mutations in Head and Neck Cancer / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.4.1. Cyclin D1 / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.4.2. P16 / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5. Bcl-2 Mutations in Head and Neck Cancer / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.1. Bcl-2 / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.1.1. Physiological Role of Bcl-2 / Lawrence Feldman / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Zane Deliu / Ardaman Shergill / Anne Meier
4.5.2. Bcl-2 Family of Proteins / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.3. Significance of Bcl-2 Overexpression / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.4. Association with Chemoresistance and Radioresistance / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.5. Role of Bcl-2 as a Marker of Prognosis / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.6. Chemotherapeutics Targeting Bcl-2 / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.5.7. Bcl-2 Summary / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
4.6. Conclusion / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
References / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
5. Immunotherapy and Cancer / Zane Deliu / Ardaman Shergill / Anne Meier / Phyo Thazin Myint / Sarah Khan / Paramjeet Khosla / Lawrence Feldman
5.1. Introduction / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.2. What Is Cancer Immunotherapy? / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.3. How Does Immunotherapy Work? / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.4. Timing of Immunotherapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.5. Combination Immunotherapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.6. Side Effects of Immunotherapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.7. Types of Cancer Immunotherapy Treatments / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.7.1. Immune Checkpoint Inhibitors / Adedoyin Victoria Aluko / James A. Radosevich / Maaly Bassiony
5.7.2. Monoclonal Antibodies and Tumor-Agnostic Therapies / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.7.3. Adoptive T Cell Therapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.8. Cancer Vaccines / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.9. Oncolytic Viral Immunotherapy (OVIs) / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.10. Non-specific Immunotherapies / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11. Immunotherapy by Cancer Type / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.1. Skin Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.2. Lung Cancer / James A. Radosevich / Maaly Bassiony / Adedoyin Victoria Aluko
5.11.3. Breast Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.4. Kidney and Prostate Cancers / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.5. Brain Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.6. Colorectal Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.7. Bladder Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.8. Cervical Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.9. Leukemia / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.11.10. Liver Cancer / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.12. Proven Studies / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.13. Cancer Immunity Pathway / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.14. Recent Developments in Immunotherapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.15. Neoantigens for Cancer Immunotherapy / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
5.16. Discussion / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
References / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
6. Predictive and Prognostic Markers for Cancer Medicine / Maaly Bassiony / Adedoyin Victoria Aluko / James A. Radosevich
6.1. Introduction / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.2. Historical Development of Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.3. Characteristics of the Ideal Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.3.1. Ideal Source of Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.3.2. Kinetics of Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.3.3. Sensitivity and Specificity for Evaluation of Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4. Utilization of Cancer Markers in Most Common Cancers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1. Colorectal Cancer / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.1. CEA / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.2. KRAS/NRAS / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.3. MSI / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.4. PD-1/PD - L1 / Elif Zeynep Yilmaz / Ebru Esin Yoruker
Contents note continued: 6.4.1.5. BRAF / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.6. Oncotype DX Colon Cancer Test / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.7. ColoPrint / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.1.8. CTC / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.2. Breast Cancer / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.2.1. ER/PR / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.2.2. HER2 / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.2.3. Oncotype DX / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.2.4. MammaPrint / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.2.5. uPA/PAI-1 / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.3. Ovarian Cancer / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.4. Lung Cancer / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.4.1. EGFR / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.4.2. ALK Rearrangements / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.4.3. ROS1 Rearragements / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.4.5. Urological Cancers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.5.1. Prostate Cancer / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.4.5.2. Renal Cancer / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5. Classification and Techniques for Studying of Cancer Markers / Ebru Esin Yoruker / Elif Zeynep Yilmaz
6.5.1. Circulating Tumor Cells as Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.2. DNA-Based Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.2.1. Microsatellite Alterations / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.2.2. cfDNA Integrity / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.2.3. DNA Methylation / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.2.4. Mutations and Single Nucleotide Polymorphisms (SNPs) / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.3. RNA-Based Tumor Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.3.1. mRNAs / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.3.2. Noncoding RNAs / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.5.4. Protein-Based Tumor Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.6. Clinical Validation of Cancer Markers / Elif Zeynep Yilmaz / Ebru Esin Yoruker
6.7. Conclusions and Future Perspectives / Elif Zeynep Yilmaz / Ebru Esin Yoruker
References / Elif Zeynep Yilmaz / Ebru Esin Yoruker
7. Dual Energy Imaging in Precision Radiation Therapy / Elif Zeynep Yilmaz / Ebru Esin Yoruker
7.1. Introduction and Overview / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2. Historical Perspective / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.1. X-Ray Production / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.2. X-Ray Interactions in Matter / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.3. Planar Image Formation / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.4. Computed Tomography / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.5. X-Ray Imaging in Radiation Oncology / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.2.6. Dual Energy Imaging in Radiation Therapy / Murat Surucu / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta
7.3. Planar Dual Energy Imaging / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.1. Theory / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.2. Planar Dual Energy Imaging Methods / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.3. Applications in Radiation Therapy / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.3.1. Image-Guided Radiation Therapy / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.3.2. Markerless Tumor Tracking / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.3.3.3. Megavoltage Dual Energy Imaging / Roberto Cassetta / Murat Surucu / John C. Roeske / Maksat Haytmyradov
7.4. Dual Energy Computed Tomography / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.1. Theory / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.2. Dual Energy Scanning Methods / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3. Applications in Radiation Therapy / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3.1. Brachytherapy Planning / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3.2. Proton Planning / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3.3. Normal Tissue Segmentation / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3.4. Assessment of Therapy Response / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.4.3.5. Dual Energy Cone Beam Computed Tomography / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
7.5. Summary and Future Directions / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
Acknowledgement / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
References / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
8. Role of Big Data in Personalized Medicine / John C. Roeske / Maksat Haytmyradov / Roberto Cassetta / Murat Surucu
8.1. Introduction / Jean-Emmanuel Bibault / Lei Xing
8.2. Concept of Big Data and the Specificities of Healthcare / Jean-Emmanuel Bibault / Lei Xing
8.2.1. Volume: How Big Is Big Data? / Jean-Emmanuel Bibault / Lei Xing
8.2.2. Variety: Where Does Big Data Come from? / Jean-Emmanuel Bibault / Lei Xing
8.2.3. Velocity: How Fast Is Big Data Generated and Interpreted? / Jean-Emmanuel Bibault / Lei Xing
8.2.4. Variability: How Does Big Data Change? / Jean-Emmanuel Bibault / Lei Xing
8.2.5. Veracity: How Accurate Is Big Data? / Jean-Emmanuel Bibault / Lei Xing
8.2.6. Value: Why Is Big Data Important? / Jean-Emmanuel Bibault / Lei Xing
8.3. Sources of Data / Jean-Emmanuel Bibault / Lei Xing
8.3.1. Genomics, Epigenomics, and Transcriptomics / Jean-Emmanuel Bibault / Lei Xing
8.3.2. Proteomics and Metabolomics / Jean-Emmanuel Bibault / Lei Xing
8.3.3. Medical Imaging and Radiomics / Jean-Emmanuel Bibault / Lei Xing
8.3.4. Clinical Informatics / Jean-Emmanuel Bibault / Lei Xing
8.4. Big Data Analytical Techniques / Jean-Emmanuel Bibault / Lei Xing
8.4.1. Machine Learning / Jean-Emmanuel Bibault / Lei Xing
8.4.2. Deep Learning / Jean-Emmanuel Bibault / Lei Xing
8.4.3. Natural Language Processing / Jean-Emmanuel Bibault / Lei Xing
8.5. Challenges in Big Data Analytics / Jean-Emmanuel Bibault / Lei Xing
8.5.1. Implementing a Big Data Approach / Jean-Emmanuel Bibault / Lei Xing
8.5.2. Developing an Information-Sharing Culture / Jean-Emmanuel Bibault / Lei Xing
8.5.3. Security Measures / Jean-Emmanuel Bibault / Lei Xing
8.5.4. Ethics in Big Data Analysis / Jean-Emmanuel Bibault / Lei Xing
8.5.4.1. Consent in the Era of Big Data / Jean-Emmanuel Bibault / Lei Xing
8.5.4.2. Privacy / Jean-Emmanuel Bibault / Lei Xing
8.5.4.3. Anonymization / Jean-Emmanuel Bibault / Lei Xing
8.5.4.4. Ownership / Jean-Emmanuel Bibault / Lei Xing
References / Jean-Emmanuel Bibault / Lei Xing.

Precision medicine in oncology /

Similar Items